Status:
UNKNOWN
Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21)
Lead Sponsor:
Victory Nutrition International, Inc.
Conditions:
Body Weight Changes
Eligibility:
All Genders
30-70 years
Phase:
NA
Brief Summary
Protocol Number: VNI/121/TrimRox: A unique stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical formulation, TrimROXTM, has been developed in a cGMP and NSF-certified manufacturing facility th...
Detailed Description
CDC reports that in the USA, the prevalence of obesity was 40% in adults between 20 and 39 years, 44.8% in adults between 40 and 59 years, and 42.8% in people 60 years and older. Furthermore, the CDC ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Agrees to sign written and audio-visual informed consent.
- Fully understand the risks and benefits of the study
- Male and Female Subjects (age: 30-70 Y)
- Subjects are deemed to be acceptable for this study by their physician
- Exclusion Criteria
- Subjects who are unwilling or uncooperative subjects
- Subjects were excluded who had impaired hepatic functions i,e., SGOT/SGPT \>2.5 X
- Subjects suffering from type 1 diabetes
- Subjects suffering from type 2 diabetes or anyone else that has a blood glucose levels \>180 mg/dl or HbA1c \> 8.
- Subjects who were suffering from coronary artery disease or high blood pressure \>180/100
- Subjects who were exhibiting abnormal hepatic or kidney functions (ALT or AST \> 2 X greater than normal value); elevated creatinine, males \> 125 μmol/L or 1.4mg/dl
- Subjects who have cancer and are suffering from a malignancy.
- Hypersensitivity to the investigational supplement
- Subjects who had used any known weight management supplement for the last 2 months.
- History of blood coagulation and bleeding (coagulopathies)
- Incidence of high alcohol intake (more than 2 standard drinks/day).
- Psychiatric disorder/disability provide signed informed consent.
- Existing medical condition of the participant, which may be detrimental to the study and subject's overall well-being.
- \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
Exclusion
Key Trial Info
Start Date :
January 23 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 9 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05283525
Start Date
January 23 2022
End Date
January 9 2024
Last Update
March 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr Bruce S. Morrison
Huntingdon Valley, Pennsylvania, United States, 19006